Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTAIN-1st
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 30 Jun 2022 Planned End Date changed from 1 Nov 2021 to 31 Dec 2022.
  • 01 May 2022 Results evaluating the cost-effectiveness of toripalimab or camrelizumab combined with gemcitabine plus cisplatin2 and GP alone by deriving survival data from the CAPTAIN-1st and JUPITER-02 trials, published in the Oral Oncology
  • 23 Jun 2021 Results comparing camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top